Epilepsy affects over 50 million people worldwide, making it one of the most common neurological disorders. Although ...
Adeno-associated virus (AAV)-based viral vectors used in human gene therapy can trigger innate immune pathways, leading to the initiation of adaptive immune responses. A new review article published ...
An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent cells and leading to syndromic hearing loss. In a new experimental study, ...
SK pharmteco today announced details of its ongoing strategic manufacturing partnership with Genethon, a France-based pioneering nonprofit research and development organization dedicated to gene ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ...
Improving the therapeutic quality and consistency of cell and gene therapies requires the adoption of enhanced Critical Quality Attributes (CQAs) throughout the development and manufacturing processes ...
Viral vector release testing requires a battery of analytical methods that, for the most part, did not exist a decade ago, and the regulatory bar rises with every new gene therapy approval. For ...
In the mid-1990s, Hiroyuki Nakai, now an adeno-associated virus (AAV) researcher at the Oregon Health and Science University, moved to the United States. Nakai quickly became fascinated with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results